000118731 001__ 118731
000118731 005__ 20240319081024.0
000118731 0247_ $$2doi$$a10.3390/biomedicines10061437
000118731 0248_ $$2sideral$$a129671
000118731 037__ $$aART-2022-129671
000118731 041__ $$aeng
000118731 100__ $$0(orcid)0009-0001-5345-6947$$aQuero, Javier$$uUniversidad de Zaragoza
000118731 245__ $$aSulfonamide-derived Dithiocarbamate Gold(i) complexes induce the apoptosis of colon cancer cells by the activation of Caspase 3 and redox imbalance
000118731 260__ $$c2022
000118731 5060_ $$aAccess copy available to the general public$$fUnrestricted
000118731 5203_ $$aTwo new families of dithiocarbamate gold(I) complexes derived from benzenesulfonamide with phosphine or carbene as ancillary ligands have been synthesized and characterized. In the screening of their in vitro activity on human colon carcinoma cells (Caco-2), we found that the more lipophilic complexes—those with the phosphine PPh3—exhibited the highest anticancer activity whilst also displaying significant cancer cell selectivity. Au(S2CNHSO2C6H5)(PPh3)] (1) and Au(S2CNHSO2-p-Me-C6H4)(IMePropargyl)] (8) produce cell death, probably by intrinsic apoptosis (mitochondrial membrane potential modification) and caspase 3 activation, causing cell cycle arrest in the G1 phase with p53 activation. Besides this, both complexes might act as multi-target anticancer drugs, as they inhibit the activity of the enzymes thioredoxin reductase (TrxR) and carbonic anhydrase (CA IX) with the alteration of the redox balance, and show a pro-oxidant effect.
000118731 536__ $$9info:eu-repo/grantAgreement/ES/MICINN/PID2019-104379RB-C21-AEI-10.13039-501100011033$$9info:eu-repo/grantAgreement/ES/MICINN AEI/PID2019-104915RB-I00$$9info:eu-repo/grantAgreement/ES/MCIU/RED2018-102471-T$$9info:eu-repo/grantAgreement/ES/DGA/E06-20R$$9info:eu-repo/grantAgreement/ES/DGA/B16-20R$$9info:eu-repo/grantAgreement/ES/CIBERObn/CB06-03-1012
000118731 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000118731 590__ $$a4.7$$b2022
000118731 592__ $$a0.897$$b2022
000118731 591__ $$aPHARMACOLOGY & PHARMACY$$b68 / 278 = 0.245$$c2022$$dQ1$$eT1
000118731 593__ $$aMedicine (miscellaneous)$$c2022$$dQ1
000118731 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b92 / 285 = 0.323$$c2022$$dQ2$$eT1
000118731 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2022$$dQ2
000118731 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b54 / 136 = 0.397$$c2022$$dQ2$$eT2
000118731 594__ $$a3.7$$b2022
000118731 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000118731 700__ $$aRoyo, José Carlos
000118731 700__ $$aFodor, Beatrice
000118731 700__ $$0(orcid)0000-0003-0553-0695$$aGimeno, María Concepción
000118731 700__ $$0(orcid)0000-0002-8251-8457$$aOsada, Jesús$$uUniversidad de Zaragoza
000118731 700__ $$0(orcid)0000-0002-3595-7668$$aRodríguez Yoldi, María Jesús$$uUniversidad de Zaragoza
000118731 700__ $$0(orcid)0000-0003-2457-3674$$aCerrada, Elena$$uUniversidad de Zaragoza
000118731 7102_ $$12010$$2760$$aUniversidad de Zaragoza$$bDpto. Química Inorgánica$$cÁrea Química Inorgánica
000118731 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000118731 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000118731 773__ $$g10, 6 (2022), 1437 [19 pp.]$$tBiomedicines$$x2227-9059
000118731 8564_ $$s1841196$$uhttps://zaguan.unizar.es/record/118731/files/texto_completo.pdf$$yVersión publicada
000118731 8564_ $$s2811390$$uhttps://zaguan.unizar.es/record/118731/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000118731 909CO $$ooai:zaguan.unizar.es:118731$$particulos$$pdriver
000118731 951__ $$a2024-03-18-16:29:41
000118731 980__ $$aARTICLE